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Purpose/Objective: The use of biological information on 
tumour control and normal-tissue complications for 
treatment plan optimisation is a first step towards 
individualised radiotherapy. However, the robustness of the 
underlying models for tumour control probability (TCP) and 
normal-tissue complication probability (NTCP) needs to be 
analysed prior to any clinical application.  
Materials and Methods: This work investigates the robustness 
of the TCP and NCTP models implemented in the biological 
optimisation tool of EclipseTM for the case of prostate cancer. 
The CT images and structure sets of ten patients previously 
treated with helical tomotherapy were imported in Eclipse 
and several biologically-based IMRT plans were created for 
each patient (dose prescription: 72 Gy in 40 fractions). The 
plans were optimised by using the NTCP Lyman model for 
rectal bleeding and bladder contracture as objective and by 
putting physical constraints to the PTV so that the tumour 
coverage was comparable to that achieved with 
TomoTherapy®. The NTCP model parameters were then 
varied individually within the ranges found in the literature. 
Among others, the values of D50, n, and m were varied for the 
NTCP model, for both rectum and bladder. Finally, a VMAT 
plan was calculated for each patient. This plan was optimized 
in order to achieve tumour coverage and DVH goals 
comparable to those of the original tomotherapy plan.  
Results: The results of this plan comparison study show that 
the NTCP Lyman model implemented in Eclipse is robust with 
respect to variations of the parameters m and n (representing 
slope and dose-volume parameter, respectively), while 
changes of D50 (within 10 %) already resulted in significant 
DVH variations. The DVH goals for rectum and bladder 
remained within the limits recommended by the QUANTEC 
survey, although V50 for the rectum was systematically higher 
than in the tomotherapy and VMAT plans. Remarkably, for 
each patient, the dose hot spots for rectum and bladder were 
significantly reduced (down to 99-102 % of the prescribed 
dose) in all biologically-optimised plans. Moreover, it was 
observed that the optimisation time was lower than for the 
VMAT plan and that extra contouring for the organs at risk 
overlapping with the PTV was redundant. 
Conclusions: Biologically-based optimisation tools allow for 
individualised dose concepts and, in principle, could be 
safely used for treatment planning of prostate cancer. They 
have the advantage of reducing optimisation time, contouring 
process, and dose hot spots. However, the NTCP model 
parameters, especially D50, should be known with 
uncertainties lower than 10 % and the DVH goals carefully 
verified. Further studies for dose prescriptions up to 80 Gy 
are currently being carried out. 
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Purpose/Objective: Peptide receptor radionuclide therapy 
(PRRT) with 177Lu labelled DOTATATE is increasingly used in 
the treatment of neuroendocrine tumours (NET) and other 
tumours expressing type 2 somatostatin receptors. In PRRT 
the kidney is generally the dose-limiting organ because low 
molecular weight radionuclide conjugates are mainly 
excreted by the kidney, where a fraction is reabsorbed, 
leading to a high locally absorbed dose. The second critical 
organ in PRRT is bone marrow whose dosimetry is usually 
determined from the activity concentration in the blood. 
Dosimetry in radionuclide therapy is commonly based on the 
MIRD model at the organ level (although MIRD also provides a 
voxel level scheme) which is not based on specific patients 
anatomy and tracers kinetics data and which can not provide 
3D dose volumes. The aim of this work was to evaluate the 
feasibility of using a more accurate, patient specific, 3D dose 
calculation method in PRRT that could also take into account 
specific patient kinetic data. 
Materials and Methods: The eleven patients enrolled in this 
study were treated with 177Lu-labeled peptides for 
neuroendocrine tumours. The mean administered activity per 
cycle was 5.7 ± 1.2 GBq. All patients underwent a series of 
five sequential SPECT-CT scans at 1, 4, 24, 44, 72 h post-
injection to evaluate the bio-distribution of the compound as 
a function of time. The SPECT-CT scanner (Symbia T2, 
Siemens Medical, Germany) was calibrated for absolute 
quantification of 177Lu using reference phantom 
measurements. Sequential SPECT-CT scans were registered to 
the first CT scan position. A deformable image registration 
algorithm was used to register all the anatomical scans of the 
sequential CT in the same frame of reference. The activity 
distribution in each SPECT scan were modified accordingly, 
using the generated deformation maps. 3D dose calculations 
were carried out using the Raydose MC code which has been 
specifically designed for molecular radiotherapy. 
Conventional radiotherapy plan evaluation metrics such as 
Dose Volume Histograms (DVHs) were generated for the 
kidneys, both average and maximum dose were extracted 
from the 3D dose map and were compared with the mean 
organ level MIRD calculations carried out with the 
Olinda/EXM software. 
Results: The SPECT activity scans reported in counts per 
voxel were converted in activity concentration (BQML) using 
a calibration factor measured in standard conditions using a 
cylindrical phantom homogeneously filled with 177Lu. 
Raydose calculations were validated in these standard 
conditions within 5% of the expected nominal dose. Raydose 
patient dose calculations were carried out on a Dell 
PowerEdge R620 dual core Xeon E-26XX processor machine 
and took, on average, 30 minutes per scan per patient to 
complete with a statistical uncertainty of +/- 2% per voxel. 
Activity integration at the voxel level was carried out 
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deforming the sequential activity maps using registered 
sequential SPECT-CT scans and with the parallelogram 
method. In 9 out of 11 cases the Olinda/EXM calculations of 
average dose absorbed by the kidneys was below the dose 
calculated by Raydose (range [8,51]%). In 2 cases the kidney 
average dose, as calculated with the Olinda/EXM method, 
were below the dose calculated with Raydose (-6,-26)%. DVHs 
and 3D dose maps provided valuable information regarding 
the uniformity of the dose distribution which would have 
been otherwise missed with an organ level approach.  
Conclusions: Following the experience obtained in this pilot 
study we conclude that it is feasible to implement in routine 
delivery of PRRT therapy patient specific 3D dose calculation 
using Raydose. Our workflow included deformable image 
registration to accurately account for changes in both 
patients anatomy and activity distribution during the course 
of the therapy. Work is in progress to use Raydose to 
optimise PRRT treatments in terms of fractionation, 
combination of isotopes and correlation with toxicity data.  
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Purpose/Objective: A second generation 3D ultrasound 
image guidance (USIG) system (Clarity, Elekta Inc), which 
allows for transperineal (TP) localization and intra-fractional 
tracking of the prostate has been evaluated for use in 
stereotactic body radiation therapy (SBRT) of the prostate at 
our institution. Here we describe our implementation of a 
prostate SBRT TP USIG protocol.  
Materials and Methods: After the development of an initial 
clinical USIG based workflow for standard fractionation 
treatment, we extended the workflow to allow for increased 
positional verification required for SBRT. Our SBRT treatment 
protocol gives 36.25 Gy in 5 fractions, every other day and 
utilizes USIG to ensure target coverage. The planning target 
volume (PTV) is defined as the CTV plus a 3 mm margin 
posteriorly and 5 mm in all other dimensions.  Patient 
alignment has to be approved by a physicist and a physician, 
both of whom have to be experienced in reading US images. 
During intra-fractional US-tracking, corrective action is taken 
if the target migrates more than 3 mm for more than 5 
seconds in any of three orthogonal coordinates. Patients were 
positioned according to SBRT protocol and aligned to skin 
marks using treatment room lasers. TP USIG was performed 
and shifts from tattoo were performed and recorded. For 
purpose of redundant verification, a transabdominal (TA) 
USIG was performed (BAT, Nomos Inc.) while TP USIG 
tracking was on. Treatment was conducted using TP USIG 
tracking. 
Results: A total of 57 fractions delivered to 11 prostate 
cancer patients were retrospectively analyzed for workflow 
performance, patient motion and agreement between two US 
image guidance devices (TA and TP). The mean of initial USIG 
shifts from skin marks based on TP positioning for all 11 
patients was 0.24, 1.25, and -4.38 mm in left-right (LR), 
anterior-posterior (AP), and superior-inferior (SI) directions 
respectively. The average difference between the two US 
systems (TP vs TA) for all patients was -0.05, -0.02, and -0.04 
mm in LR, AP and SI directions respectively. The respective 
standard deviations were 0.14, 0.34 and 0.27 mm. Patient 
alignment was corrected if indicated by tracking. Intra-
fractional tracking data was analyzed and will be presented 
(see Image 1). 
 
 
 
Conclusions: 11 prostate SBRT patients treated in our clinic 
were localized using two USIG systems which showed average 
agreement to less than 0.5 mm in all three principle 
directions (LR, AP, SI). Intra-fraction tracking allowed us to 
reduce treatment planning margins to 3 mm posteriorly and 5 
mm elsewhere, due to the ability to track and correct for 
motion during treatment. 
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Purpose/Objective: ProtecT is a phase 3 clinical trial [1] 
comparing prostate cancer mortality for patients with 
clinically localised prostate cancer randomly assigned to 
active monitoring, radical prostatectomy or 3D conformal 
external beam radiotherapy.  
Trial results are anticipated for 2016 and the purpose of this 
work is to assess the quality of treatment plans produced for 
participants randomised to receive radiotherapy. 
Materials and Methods: 545 of the participants, recruited 
across 9 UK cities were randomised to receive radiotherapy. 
3D conformal external beam radiotherapy was used to deliver 
74Gy to the isocentre in 2Gy fractions in 2 phases. During 
phase 1 a dose of 56Gy was prescribed to a target volume 
including prostate and seminal vesicles and during phase 2 a 
dose of 18Gy is prescribed to a target volume surrounding 
prostate only. To ensure consistency and comparability of 
radiotherapy between centres a detailed radiotherapy 
protocol was developed. To assess the quality of radiotherapy 
plans, 13 quantities were measured and a deviation recorded 
